血栓形成倾向患者接种COVID-19疫苗后静脉血栓栓塞症
本研究利用梅奥诊所电子病历分析2020年11月1日至2021年11月1日接种COVID-19疫苗的成人血栓形成倾向患者,比较接种后90天与接种前90天经影像确诊的急性静脉血栓栓塞症(VTE)事件。
要点
- 血栓形成倾向患者接种COVID-19疫苗后90天VTE发生率与接种前90天相比无显著差异。
- 总体调整后风险比0.81(95%CI 0.53-1.23),未达统计学显著。
- 结果与既往研究一致,可为遗传性或获得性血栓形成倾向患者提供额外 reassurance。
核心结论
- 在接种COVID-19疫苗的血栓形成倾向患者中,接种后90天与接种前90天相比急性VTE风险未见增加。
研究设计与样本
- 利用梅奥诊所企业电子病历分析2020年11月1日至2021年11月1日期间接种COVID-19疫苗的≥18岁患者。
- 主要结局为首次疫苗剂量日期前后90天内经影像确诊的急性VTE。
主要发现
- 血栓形成倾向患者接种后VTE 39例 vs 接种前51例(0.64% vs 0.84%,p=.20)。
- 因子V Leiden或凝血酶原基因突变患者接种前VTE 27例 vs 接种后29例(0.61% vs 0.65%,p=.79)。
- 抗磷脂综合征患者接种前VTE 6例 vs 接种后4例(0.59% vs 0.39%,p=.40)。
- 接种后90天与接种前90天总体VTE率比较,调整后风险比0.81(95%CI 0.53-1.23)。
临床怎么用
- 原文结论认为结果与既往研究一致,可为遗传性或获得性血栓形成倾向患者提供额外 reassurance。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with thrombophilia remain concerned about venous thromboembolism (VTE) risk with COVID-19 vaccinations. The aim of this study was to examine VTE outcomes in patients with inherited or acquired thrombophilia who were vaccinated for COVID-19. Vaccinated patients ≥18 years between November 1, 2020 and November 1, 2021 were analyzed using electronic medical records across the Mayo Clinic enterprise. The primary outcome was imaging confirmed acute VTE occurring 90 days before and after the date of the first vaccine dose. Thrombophilia patients were identified through laboratory testing results and ICD-10 codes. A total of 792 010 patients with at least one COVID-19 vaccination were identified. Six thousand sixty-seven of these patients were found to have a thrombophilia, among whom there was a total of 39 VTE events after compared to 51 VTE events before vaccination (0.64% vs. 0.84%, p = .20). In patients with Factor V Leiden or prothrombin gene mutation, VTE occurred in 27 patients before and in 29 patients after vaccination (0.61 vs. 0.65%, p = .79). In patients with antiphospholipid syndrome, VTE occurred in six patients before and four patients after vaccination (0.59% vs. 0.39%, p = .40). No difference was observed in the overall VTE rate when comparing the postvaccination 90 days to the prevaccination 90 days, adjusted hazard ratio 0.81 (95% confidence interval: 0.53-1.23). In this subgroup of COVID-19 vaccinated patients with thrombophilia, there was no increased risk for acute VTE postvaccination compared to the prevaccination timeframe. These results are consistent with prior studies and should offer additional reassurance to patients with inherited or acquired thrombophilia.
引用
- Houghton DE, Wysokinski WE, Padrnos LJ, et al. Venous thromboembolism after COVID-19 vaccination in patients with thrombophilia. Am J Hematol. 2023. PMID: 36660880. doi:10.1002/ajh.26848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。